byiShook Opinion
Apr 29, 2025 - 17:20
BridgeBio's new heart drug — a rival to Pfizer's blockbuster Vyndaqel — smashed sales expectations in its first full quarter on the market. The post BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations appeared first on Investor's Business Daily.
BridgeBio's new heart drug â a rival to Pfizer's blockbuster Vyndaqel â smashed sales expectations in its first full quarter on the market.
The post BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations appeared first on Investor's Business Daily.